A pricing plan with unintended consequences
The policy’s stated goal is to protect Americans from paying high prices and subsidizing the rest of the world’s cheaper medicines. Under deals reached last year, the “most favored nation” price is based on the average of prices in a basket of reference countries, and in return companies were spared tariffs for three years.
“You have companies saying, ‘Well maybe I won’t enter the market there because it’s just going to be used against me in the United States.’” — Ipsita Smolinski
The program is still being rolled out and could eventually lower drug prices. In 2026, the costs of popular weight-loss and infertility drugs fell as part of the deals. Trump also said companies would sell newly launched drugs at lower prices on the TrumpRx website; Amgen, for example, offered a 60% discount on Repatha, which lists for about $6,900 a year.
Drugs withdrawn or delayed
Some drugmakers have chosen to pull medicines or skip launches in certain markets so they don’t have to lower what they are paid in the US. Notable cases include:
- In February, Amgen withdrew a cholesterol-lowering drug from Denmark over fears that its Danish price would affect its US price.
















